![](https://www.coherentbio.com/wp-content/uploads/2024/03/图片8.png)
CBP-1018
CBP-1203
![](https://www.coherentbio.com/wp-content/uploads/2024/03/图片7.png)
CBP-1008 / CBP-1018
CBP-1019 / CBP-8088
![](https://www.coherentbio.com/wp-content/uploads/2024/03/图片6.png)
CBP-1019
![](https://www.coherentbio.com/wp-content/uploads/2024/03/图片5.png)
CBP-1018
CBP-8088
![](https://www.coherentbio.com/wp-content/uploads/2024/03/图片4.png)
CBP-1008
CBP-1019
![](https://www.coherentbio.com/wp-content/uploads/2018/08/1.png)
√ Dual tumor antigen targeting
√ Retains specificity / affinity
√ Cover Low Receptor expressions
√ Broad Indications
![](https://www.coherentbio.com/wp-content/uploads/2018/08/2.png)
To help stakeholders in government and business make smart decisions.
![](https://www.coherentbio.com/wp-content/uploads/2018/06/3.png)
To help stakeholders in government and business make smart decisions.